Molecular Biomarkers in Peri-Implant Health and Disease: A Cross-Sectional Pilot Study

Simple item page
dc.coverageDOI: 10.3390/ijms23179802
dc.creatorChaparro, Alejandra
dc.creatorBeltrán, Víctor
dc.creatorBetancur, Daniel
dc.creatorSam, Ye Han
dc.creatorMoaven, Haniyeh
dc.creatorTarjomani, Ali
dc.creatorDonos, Nikolaos
dc.creatorSousa, Vanessa
dc.date2022
dc.date.accessioned2025-11-18T19:54:39Z
dc.date.available2025-11-18T19:54:39Z
dc.description<p>Background: The aim of this feasibility study was to investigate the concentration level of CCL-20/MIP-3α, BAFF/BLyS, IL-23, RANKL, and Osteoprotegerin in the Peri-Implant Crevicular Fluid (PICF), from patients diagnosed with peri-implant mucositis and peri-implantitis, and to compare them with PICF from patients with healthy implants. Methods: Participants with at least one dental implant with healthy peri-implant tissues, peri-implant mucositis, or peri-implantitis were included. PICF was collected using paper strips from healthy and diseased peri-implant sites (n = 19). Biomarker levels were analyzed using a custom Multiplex ELISA Assay Kit. Results: In comparison to peri-implant health, the peri-implant mucositis group showed an increased concentration of CCL-20 MIP-3α, BAFF/BLyS, IL-23, RANKL, and Osteoprotegerin. The peri-implantitis group had the lowest median concentration of Osteoprotegerin (1963 ng/mL); this group had a similar concentration of RANKL (640.84 ng/mL) when compared to the peri-implant health group. BAFF/BLyS (17.06 ng/mL) showed the highest concentration in the peri-implantitis group. Conclusions: This feasibility study suggests that IL-23 and RANKL may help to elucidate the pathogenesis during the conversion from peri-implant health to peri-implantitis. Further research is required in BAFF/BLyS for the early diagnosis of peri-implantitis.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/17f794b1-954d-4384-b799-b4e5c00b5bef
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/58871
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.23 (2022) date: 2022-08-29 nr.17 p.1-8
dc.subjectBiomarkers/analysis
dc.subjectCross-Sectional Studies
dc.subjectDental Implants/adverse effects
dc.subjectGingival Crevicular Fluid
dc.subjectHumans
dc.subjectInterleukin-23
dc.subjectMucositis
dc.subjectOsteoprotegerin/analysis
dc.subjectPeri-Implantitis/diagnosis
dc.subjectPilot Projects
dc.titleMolecular Biomarkers in Peri-Implant Health and Disease: A Cross-Sectional Pilot Studyeng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
PURE